Stats

Recovered Oraclefull139225characterplainfiling andselectedlaterMD&A/RiskFactors https://www.sec.gov/Archives/edgar/data/1341439/000119312526389274/orcl-20260831.htm . Premise1: original laterMD&A explicitlyfullyutilized20bnATM/approx141mnewshares;19.9bnnet proceedsarepastfunding, not remainingcapacity. Cash/securities37.077bn andmanagement12monthliquidityassertion+discretionarycapexflexibility arecounterarguments againstimminentfundingfailure. Premise2: OCF23.103bn includes11.363bnfinancingprepayments,capex28.499bn,FCF-5.396bn; simpleexprepayFCF-16.759bn diagnostic notGAAP. Prior288bnfutureleasesnotPVdebt. No newearningsdate fromfinancingfacts. Copart actualSep10Q&A inSep11exhibit https://www.sec.gov/Archives/edgar/data/900075/000119312526388383/d138398dex992.htm clarifies firstfull-yearaccretionFY28, currentyearbreakeven; cash-funded nofinancingcondition,customaryregulatoryreview,end2026expectedclosurenotfixeddate. CEO>2bnpostdeal cash isforecast. Distinctbrands retained,butbuyers/logistics integrated;capex/training/technologyinvestment needed. Q4USinsuranceunits-7.5%,cost/car+12.7%,opincome-10.6%contradictpureliquiditybullstory. CFO17m longhaulcostincrease maysupportnewfees,counter toallcostswaste. Tenderstillnotcommenced per https://www.sec.gov/Archives/edgar/data/900075/000119312526388383/d138398dsctoc.htm . Conclusion watcheconomics, no runuporder ormergerdateguess. Q&A coveragegapclosed; annualORCL10Kriskreviewandfuturedealtermsremainseparatework.

Primary July15 original https://www.conagrabrands.com/news-room/news-conagra-brands-reports-fourth-quarter-and-full-year-results-prn-122958 and Aug31 https://www.conagrabrands.com/news-room/news-conagra-brands-to-release-fiscal-2027-first-quarter-earnings-on-september-30-2026-prn-122962. Premises: (1) FY26 FCF979m versus dividends670m leaves309m before other cash uses, net debt7.1bn/leverage3.83x. FY27 capex550m versus423m means+127m/+30.0%, while organic salesguided-3to-1%,margin10to10.5%,EPS1.40to1.50. (2) Dividend cutto0.70annual from1.40 conserves approximately335m/year at479mshares, assumptionconstant shares notissuerforecast. (3) At14.60Sep11SIP, forwardadjustedEPSmultiple9.73–10.43x and annualdividendyield4.79%; valuationmultiples are proxies notintrinsicvalue. (4) Q4reported3.6%growth includes7.7pp53rdweek, whileorganicflat combines+1.6price/mix/-1.6volume, not organicgrowth. Conclusion: affordable earningsrunupcandidate, not automaticallycheap; fundamental recovery needsvolume andcashprogress onSep30. Countercase: lowexpectations,newCEO,dividendretention andleadingbrands could permitasymmetricrebound. Bindingconstraint isnetpre-eventedge, notbalance-sheetimminentfailureor49.14affordability. Hardlimit: netleverageforecast4x andcapexrising reduce cash flexibility. Facts above fromissuer; runupprobabilityunknownuntiltest; noorder.

Today changed: Sep11Oracle10Q original https://www.sec.gov/Archives/edgar/data/1341439/000119312526389274/orcl-20260831.htm accessibleviaEDGARCLI, first60kchars only. (1) Q1 OCF23.103bn includes11.363bnfinancingprepayments;capex28.499bn -> FCF-5.396bn. (2) NetATM equityissuance19.909bn fundsbuildout; exfinancingprepaymentFCF-16.759bn isanalyticalbridge, notGAAP. (3) Additional288bnleases expectedcommenceFY27Q2–FY29 for15–19years; notPVrecognizedliability. RPO664bn with13%=86.32bnexpectedrevenuewithin12months is not cash/profit andcannotoffsetleasesdollarfordollar. Strongestbear: longfixedcapacitycommitments plusdilution require utilizationandmarginstocatchup. Counter: customerprepaymentsandlargecontractedbacklogsharefundingrisk andcouldproducehighfuturecash. Threeorders: buildoutfunding -> equipment/powerpaymentsandfutureleaseobligations -> stockholdercashdependsonprofitableusagewithlessflexibility. Nonewrunupdate; noorder. CPRT Sep11 https://www.sec.gov/Archives/edgar/data/900075/000119312526388383/d138398dsctoc.htm ispreliminarytendercommunications, notcommencement/expiry. 1 plannedACVdeal ->2 regulator/integration/cashcommitment ->3 returnsoncapitalmustbeatcashalternative; counterdealerwholesaleplatformsynergies. No fixedarbitragedate fromSC TO-C. ADBE latest2filingsonlySep10/Sep8, no newSep11returned; priorcashanalysisreused, no organicgrowthbridgeverified. FullCPRTexhibittranscript andOraclelater10Qsections are explicitgaps, not presumedunchanged.

Premises: (1) September11 BLS August CPI +0.4% MoM, core +0.3%; core YoY slowed to2.4%. (2) Real hourly pay -0.1% MoM, while longer hours lifted real weekly pay0.2%. (3) Michigan preliminary sentiment47.8 from51.7, one-year inflation expectations4.6% from4.0%. (4) Census applications531728 fell7.8%, projected next-four-quarter formations28501 fell4.6%; these are not actual August startups. Conclusion: demand-sensitive HOFT/SCHL/KR deserve scrutiny of volumes, margins and cash; these releases do not supply a dated company run-up edge. Strongest countercase: KR kept EPS5.10–5.30 and FCF2.7–2.9bn guidance despite1pp sales-midpoint cut; accounting/pharmacy headwinds differ from unit demand, and weekly purchasing power improved. Facts from agency surveys/admin records have different populations and collection lags. No prior forecast was registered, no measured surprise or causal claim about today's tape. Sources https://www.bls.gov/news.release/cpi.nr0.htm ; https://www.bls.gov/news.release/realer.nr0.htm ; https://www.sca.isr.umich.edu/ ; https://www.census.gov/econ/bfs/current/index.html ; https://www.thekrogerco.com/ir-feed-item/kroger-reports-second-quarter-2026-results-and-updates-guidance-for-2026/ .

No holdings, so these are watchlist challenges, not exit instructions. SRRK primary https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-announces-fda-approval-isembyldtm-apitegromab-mstn (Sep11 18:25EDT RSS) reports ISEMBYLD approval19days beforeSep30goal. Premises:1 regulatory risk for this US indication is resolved;2 eligible patients must already receiveSMN2-targeted therapy and shipping/payeraccess are prospective;3 voucher award is not cash sale. Bear: launch conversion, fractures9%vs2%, infusion logistics and manufacturing still constrain cash; approval has already arrived so cannot buy aSep30run-up. Countercase broad age>=2label, firstmuscle-targeted treatment and voucher can support repricing, but no independent net postapproval strategy established. HOFT Sep11original https://investors.hookerfurnishings.com/news-releases/news-release-details/hooker-furnishings-reports-profitable-quarter-and-first-half :1 Q2OI1.3m contains~3.8mnetoperating tariffbenefit (4.3COGS-.5customercredits);2 simple normalizedOI~-2.5m;3 revenue-8.7%and noadditionalmaterialtariffrecoveries expected. Bear: headline profits overstate recurring demand and cashrelease cannot recur. Countercase cash18.7m/no bankdebt, backlog+6.2%YoY and lasting17.5m annualcostcuts may support recovery; July improved exrefund permanagement, not independently quantified. H1FCF24-1.1=22.9m, subtract7.9refund=>15m before other workingcapital; not perpetual cash. Valid conclusion reject automatic entries; financial soundness limited by rounded accounting bridges and issuer bias, no market valuation model yet.

1. Q2 comps fell2.1%; the37 days throughSeptember7 fell3.5%, so earlyQ3 does not show demand recovery. 2. Six-month OCF-27.276m less4.880m capex gives-32.156m FCF; cash buybacks28.972m raise combined drain to61.128m, versus63.359m fall in cash plus securities sinceJanuary31. 3. Inventory is approximately flat YoY, reducing evidence for a large inventory buildup. Conclusion: no cash-backed recovery signal. The issuer's positive35.7m OCF narrative refers to the year-over-year cash bridge, not the negative six-month table; different periods reconcile both. Strong countercase is seasonally strong holiday cash and international growth; require paid cash and US traffic recovery rather than assume annualized H1 burn. Earnings completed, no new run-up entry. Source https://www.sec.gov/Archives/edgar/data/1318008/000117184326005980/exh_991.htm .

1. SEC Q4 results show gross margin41.7765% versus45.3044%, a3.5278pp contraction despite2.4% revenue growth. 2. FY OCF1604.492m less capex337.363m gives1267.129m FCF; lower investment explains improvement over prior1230.760m despite lower OCF. 3. ACV's approximately1900m equity price is1.4995x FY FCF; $10.50 cash tender remains subject to majority acceptance and HSR, with no financing condition. Conclusion: acquiree platform benefits may help future growth, but they do not reverse current margin pressure. Issuer forecasts EPS accretion only FY2028 onward. Exact tender commencement/expiry unconfirmed; no invented merger deadline or arbitrage order. This recovers earlier results/agreement gaps; operating unit detail and full Q&A remain gaps. Sources https://www.sec.gov/Archives/edgar/data/900075/000119312526387902/cprt-ex99_1.htm ; https://www.sec.gov/Archives/edgar/data/900075/000119312526388064/d138322d8k.htm ; https://www.sec.gov/Archives/edgar/data/900075/000119312526388064/d138322dex991.htm .

1. Q3 OCF $2.523bn less $85m capex gives $2.438bn FCF, covering $2.232bn cash buybacks 1.0923x. 2. GAAP EPS4.62 versus adjusted6.13 differs by1.51; stock/deferred compensation accounts for1.38 of that bridge. 3. Q4 revenue midpoint6.825bn is only0.962% above rounded Q3 sales6.76bn. Conclusion: cash generation supports the business, but acquisition-inclusive growth and product adoption percentages do not isolate organic AI monetization. Countercase: Firefly and enterprise adoption can compound into paid expansion. Reconsider upon a complete organic revenue/ARR bridge and durable cash conversion; no run-up trade after released earnings. Exact table OCF2523 supersedes rounded2520 used in exploratory arithmetic. Sources https://www.adobe.com/cc-shared/assets/investor-relations/pdfs/01906202/au56y4ter.pdf ; https://www.adobe.com/cc-shared/assets/investor-relations/pdfs/01906202/c6yetrerew.pdf .

1. September 10 issuer statements report $23.103bn Q1 OCF and $28.499bn capex. 2. Financing-component customer prepayments supplied $11.363bn, or 49.184% of OCF. Subtracting them as a sensitivity leaves $11.740bn OCF, still 44.226% above prior Q1; subtracting capex then gives -$16.759bn. This is not a GAAP correction or a forecast of recurring cash. 3. Net ATM issuance supplied $19.909bn. Conclusion: delivery growth is real issuer-reported evidence, but backlog growth is not self-funded equity cash flow. Strong counterargument: customer financing aligns funding with contracted demand and reduces external financing needs. What changes the view: documented conversion to profitable services and less capital required per incremental paid revenue. No purchase: earnings already occurred; no new dated run-up. Sources https://investor.oracle.com/files/content_files/1q27-pressrelease-September_FINAL.pdf ; https://www.prnewswire.com/news-releases/oracle-announces-q1-results-driven-by-triple-digit-growth-in-cloud-infrastructure-revenues-302875728.html .

Premises:1 June29issuerMay31H1CFO174.671m lesscapex102.076m=FCF72.595m,down44.80895%yearonyear;Q2FCF209.717m versusadjusted242.324m includes32.607mfactoringadjustment. 2 H1adjustedFCF97.711m;FYguide630–650mmid640 requiresH2542.289m,271.1445m/quarter,5.549928xtheH1total. This isrequiredarithmetic,notforecast;seasonalitymakeshalvesunequal. 3 H1GAAPop213.980m/interest143.391m=1.4923coverage;Maycash255.566m,carryingnetdebt4329.308m. At27usingMay60.863mshares:marketcap1643.301m,simplifiedEV5972.609m/annualizedH1adjustedEBITDA1391.112m=4.2934x;price/FYadjustedEPSguidemid=2.4534x. These useoldbalances,notTTM/currentEV; omitotherclaimsandcannotsetfairvalue. Bullcasecashseasonality+restructuringsavingsfunddeleveraging;countercaseclientskeepAIbenefitsandfactoringmasksconversion. Conclusionwatchcash/debtratherthancheapadjustedEPS. Original https://ir.concentrix.com/news/news-details/2026/Concentrix-Reports-Second-Quarter-2026-Results/default.aspx ; prices https://runway.adityaperswal.workers.dev/data/stock-bars

Premises:1 Jun30cash4.659m,H1CFO-1.728m. SummedstatementWCsource+2.161m meanspreWCcash-3.889m; MD&AcallsWC2.2mused,anunresolvednarrativesignerror. ExcludingrelatedAPpaydown3.714malonegives+1.986mCFO, butalsoexcludingthirdpartyAPincrease2.461mgives-.475m.2 H1monthlypreWCburn.6482m/simplecash7.19monthsversusreportedburn.288m/16.18months; thesearemechanicalsensitivitiesfromJun30,notrunwayforecasts; seasonality,launchcostsandpullforwardinvalidateconstantburn. Goingconcerndoubtpersists.3 Costresetstructuralbutcurrent80%GMnotinfinite:annualAmeluzearnout12%<=65m/15%onallrevenueabove65m.65->65.01madds1.9515mearnout;constant77%contributionrequires2.534mextrarevenueoffset,illustrationnotforecast.4 Jun30potentialshares43.55556m;July8conversion.552483malreadyinAug11common14.852359m;cannotnaivelyaddwithoutadjustment. Debtconversiondoesnotbringcash;outofmoneywarrantproceedsunavailableassumption. Conclusion realoperatingimprovementdoesnotestablishpre-eventpayoff. Bullcaselegacyutilizationfundslaunch; needsactualpostrestrictioncashandclearance. Sources https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm ; https://www.sec.gov/Archives/edgar/data/1858685/000149315226037610/ex99-1.htm .

1 Issuer Sep8published announcement recovered from public posts API used by neovolta.com client: Sep23AMC FY26 results,17ETcall; exitSep22 for anyfuturepre-eventposition. CalendarOct5weekwrong.2 Aug31signedSKOn agreement9GWhcells2027–31 isinputprocurement; additional9GWhpackpurchasecollaboration isframework. Combined18GWhfive-yearactivity not18GWhfirm annualoutput orrecognizedrevenue. Initialsupplyaverage1.8GWh/year; combinedactivity3.6GWh/yearsimpleaverage versus8GWh2028annualcapacitytarget. These have different scopes/units anddo notmeasureutilization.3 May14quarterendedMar31:Q3revenue2mflat,GP.9m/~46%vs26%mix;opex3.6m,netloss3m,cash11.5m;Q3grossprofitcovers25%ofopex. Nine-monthrevenue13.3m+262% isnotQ3growth. April3mrevolver andMay8mPhase2contributionplan werefinancingcontext,notcurrentavailablecash. Luminia1.9m40unitPO isfirmerthan39mpipeline; implied47500perunit notunitprofit. 2GWh*$200/kWh=$400millustration explicitlynotforecast.4 Countercase signedcells,manufacturingcontrol80%andmarginmixcanenablegrowth; cashcapex/customeracceptance/financing stillneedcurrentverification. Inference: supplycommitmentsbeforecustomerconversioncanworsenworkingcapital,so noentryfrom18GWhheadline. CLItrenddiagnosticnotdate-eventedge; exacteventstudyand15minexitvalidationmissing. Source https://neovolta.com/press-releases ; publicpublishedposts via clientJS https://neovolta.com/assets/index-Cjvt5RDe.js ; slugs neovolta-q4-fy26-earnings-call-timing / neovolta-reports-third-quarter-fiscal-2026-financial-results / neovolta-announces-strategic-u-s-battery-cell-supply-and-bess-manufacturing-coll . Recipe saved separately.

1 TBN Sep8firstgas confirms deliveredproduct but40TJ/day isearly2027fullcontractedforecast. Fullannualized40*365=14600TJ grossproject, notachieved ornetTBN; discountedinterruptiblecommissioningprice, noactualvolume/netback supplied. Mar31historicalcash88.151m plusrestricted13.766m distinct;9mOCF-27.037/investing-112.793=>139.830mcombinedburn,15.5367m/month,financing194.048m. Countercase Aprilraise/firstsales canimprovefunding; oldMarcashnotcurrentrunway. No valuation fromunpricedgas. 2 CNXC Q2endedMay31 revenue2462.5m+1.9%,GAAPoperating95.4m-35.7%,margin3.9%vs6.1%;nonGAAP292m/11.9%,stilldown3.9%. OCF257.9m/adjustedFCF242.3m,adjustedFCF definition removesfactoringchange; cannot callalladjustedcashunrestricteddistributable. Q3guide2465–2490mrevenue/121–131mGAAPopincome/2.65–2.77adjustedEPS. Cash255.566m,currentdebt650m,longtermnet3934.874m implycashpooragainstdebt; capitalreturn storyneedsCFandfinancing,notcheapEPSmultiple. 3 Both issuers benefitfrompromotingcapacity/adjustedmetrics; customers maycapturevalue viagasdiscounts orAIcostsavings. Conclusion watchactualcash atconfirmedTBN Sep25USAM andCNXC Sep29AMC; no liveproposal fromheadlines. Validity: reportedgrowth alone doesnotestablishshareholdercash; soundness limitedoldperiodandmissingnetbacks. Sources https://ir.tamboran.com/news-events/press-releases/detail/49/tamboran-delivers-first-gas-sales-from-the-beetaloo-basin ; https://ir.tamboran.com/sec-filings/all-sec-filings/content/0001628280-26-034593/0001628280-26-034593.pdf ; https://ir.concentrix.com/news/news-details/2026/Concentrix-Reports-Second-Quarter-2026-Results/default.aspx .

1 LatestreviewedfinancialperiodMar31quarter: OCF3.489m-cashcapex1.263m=2.226m versusdiv4.261m;52.24%coverage. Nine-month10.799mFCF/12.613mdiv=85.62%. 2 Q3equity3.594mnetand2mnewborrowings coincidewith6.697mOCFlessallinvestinglessdiv deficit;cannot earmarkindividualfundingdollars. Cash2.616m/debt56.5m and6.78%rate constrain. 3 Sep10declaration.12,recordSep21/paySep30, establishes obligation notcoverage; 12.5%annualizedyieldat3.84 assumes4unchangedpayments. Bearcase commodityweakness orroyaltydelays leave payouts competing withdebt/acquisitionfunding. Strongcountercase forecast23royaltywells andcapital-lightmix improveQ4cash; Marchisold, no claimcurrentcoverageunchanged. Incurredcapex1.6m versuscash1.263m aredifferentdefinitions. UpdateonSep15AMCactualcash,notdividendheadline. Sources https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-third-quarter-2026-results ; https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-declares-012-share-cash-dividend-fiscal-q1 .

1 ORCLQ1endedAug31:OCF23.103bn includes11.363bnfinancingcomponentprepayments,capex28.499bn=>FCF-5.396bn;19.909bnnetATM. RPO664bnnotcash. 2 ADBEQ3endedAug28OCF2.523bn/capex.085bn=>FCF2.438bn,36.065%revenue;organicARRbridgeunknown. 3 ZUMZH1endedAug1OCF-27.276m/capex4.880m=>-32.156m;37dayQ3comps-3.5%. Trailing35.7mOCFnarrativeusesdifferentperiod. 4 CPRT/ACVjointissuerdeal10.50cash/~1.9bnequity,no financingcondition,buttender/HSRremain andnoexactclosedate;45%premiumhistoricalnotcurrentupside. EPMdeclared.12dividendnotcashcoverage. Conclusionnoqualifyingpreevententry;strongcountercaseADBEcashandORCLfundedcapacitycouldsupportgrowth,requiresprice/organic/independentpayoffwork. Sources https://investor.oracle.com/files/content_files/1q27-pressrelease-September_FINAL.pdf ; https://www.adobe.com/cc-shared/assets/investor-relations/pdfs/01906202/au56y4ter.pdf ; https://ir.zumiez.com/news-releases/news-release-details/zumiez-inc-announces-fiscal-2026-second-quarter-results ; https://investors.acvauto.com/news-events/press-releases/detail/113/copart-to-acquire-acv-expanding-position-across-the-vehicle-remarketing-ecosystem .

1 LOVEoriginalJune11andSep10guides:EBITDAmid40.5→33.5m, currentrefundexcluded;old3.6mrefundtreatmentnotexplicitlybridged,so-7mnominalnotcleanorganiccut.2 FullissuerQ2tables H1OCF-11.429/investing-12.204=-23.633m despite21mrefund,cash68.804m; SEC403today butissuerfallbackmatchespriorSEC.3 TLXApr10originalSep11PDUFA/noFY26Pixclararevenue; latest3RSSnonewdecisionnotpendingproof. SRRKreplay42charsnotfullcommentary, facilityresolutionunknown. Conclusionnoincrementalevidenceoffundedprofitable3Rrunup. CountercaseLOVEH2seasonalityandregulatoryclearancemayimprovefuturecash; fundamentalimprovementwouldnotvalidateentryalone. Sources https://investor.lovesac.com/news-events/press-releases/detail/167/the-lovesac-company-reports-second-quarter-fiscal-2027 ; https://investor.lovesac.com/news-events/press-releases/detail/164/the-lovesac-company-reports-first-quarter-fiscal-2027 ; https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ ; https://kvgo.com/2026-biopharma-conference/scholar-rock-sep-2026 .

1 LOVEAug2H1originalSEC confirms21mrefund inclinterest,OCF-11.429m/investing-12.204m=>-23.633m vsprior-42.408m;18.775mimprovementincludesrefund,notallorganic. Cash68.804m; avoiddistressclaim.2 SRRKAug21 original saysFDAdecisionanytimethroughSep30,alternatefacilityreview,EUwithdrawal afterCatalentOAI; thisisnotnewfacilityclearance.3 TLXApr10Sep11goaldate reverified;noPixclara revenueinFY26guideasofApr10. BoundedRSSshowsnonewdecision,butcannotestablishpendingstatus. Conclusion fundamentalsdo notsupplytested3Rstockpayoff. CountercaseLOVEH2seasonalityandFDAclearancecouldimprovecash; evidencewouldupgradefundamentalview butneedsindependentstockvalidation. Sources https://www.sec.gov/Archives/edgar/data/1701758/000162828026061220/love-20260802.htm ; https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-provides-update-global-apitegromab-regulatory ; https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ .

Premises1 LOVE10QendedAug2confirms21mrefund,OCF-11.429m/investing-12.204m/financing-9.416m/cash68.804m; sumOCF+investing=-23.633m andtotalcashchange-33.049m. Realrefundcashdoesnotproverecurringcashgeneration.2 June11genericoutlook3.6mrefundvsSep10explicitEBITDAexclusion means40.5→33.5m nominalmidpoint cannotbe labelledexactorganiccut; registrationonlypubliccallstillunread.3 SRRK200JSshellnotreplaycontent,RSSlatestSep2FSHDnotnewSMAfacilityresolution; TLXSep11goaldate confirmedApr10origin, Sep10Ga68article notdecision. Conclusion zeroentry, uncertaintyretained. Strongcountercase LOVEinnovation/H2seasonality andpositiveFDAdecisions couldimprovevalue; requiresactualorganiccash/fullpipelineevidence and independentpriceedge. Issuerleansoptimistic; SECsamecompanynotindependentcorroboration. Sources https://www.sec.gov/Archives/edgar/data/1701758/000162828026061220/love-20260802.htm ; https://investor.lovesac.com/news-events/press-releases/detail/164/the-lovesac-company-reports-first-quarter-fiscal-2027 ; https://investor.lovesac.com/news-events/press-releases/detail/167/the-lovesac-company-reports-second-quarter-fiscal-2027 ; https://kvgo.com/2026-biopharma-conference/scholar-rock-sep-2026 ; https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ .

Premises1 Sep10issuerQ2releaseexcludesIEEPArefundfromadjustedEBITDA;21mreceivedsplit20COGS/.3inventory/.7interest. ExrefundGM56%,Q2adjEBITDA-1.252m; priorFCF-23.633mretained22799.2 Q1issuer164outlookincluded3.6mrefundincludinginterestbutgenericnonGAAPdefinitiondidnotexplicitlyexcludeit.3 CurrentFYsalesmid700vs720(-2.7778%),EBITDA33.5vs40.5(-17.284%) nominal. Ifentireold3.6included,oldrestated36.9implies-9.2141%; thisisconditionalnotexactbecauseinterestpartandcallbridgeunknown. Conclusion nominalcutnotcleanorganiccut; realcashimprovesliquiditybutdoesnotproveacceleration. Strongcountercaseinnovations/productmixboostH2; requireorganicorders/cashandindependentpriceedge. Issuerpubliccallregistrationonly, no claimheardQ&A. Sources https://investor.lovesac.com/news-events/press-releases/detail/164/the-lovesac-company-reports-first-quarter-fiscal-2027 ; https://investor.lovesac.com/news-events/press-releases/detail/167/the-lovesac-company-reports-second-quarter-fiscal-2027 .

Premises: (1) Sep10 issuer release and 10Q for Aug2 quarter report sales161.245m(+.4454%),comps-1.9%,GM68.4%; ex-refundGM55.968%=56.0%,down40bp. (2) Actual21mrefund+interest, not future receivable; Q2 net7.429m includes .86EPSrefundbenefit vs .51EPS reported, adjustedEBITDA-1.252m. (3) Python H1OCF-11.429 minusPPE11.592/patents.612=FCF-23.633m vs-42.408m; excluding receipt sensitivity-44.633m, not tax-normalized or forecast. (4) FYsales midpoint720→700m(-2.7778%); nominalEBITDA40.5→33.5m(-17.284%) not clean organic surprise because treatment of original3.6mrefundguide needs call bridge. Cash down33.049m sinceFeb1, inventory+22.431%; Augustyearonyearinventory+5% differsperiod. Conclusion: real refund improves financing flexibility, but does not demonstrate sustainable operating acceleration. Countercase newproducts/high-endconfiguration could improve futuremix; need incrementalorders/retainedcash. Valid inference for withholding new thesis, not proof equity must fall. No valuation/stockpayout inferred. Sources https://investor.lovesac.com/news-events/press-releases/detail/167/the-lovesac-company-reports-second-quarter-fiscal-2027 ; originalguide https://investor.lovesac.com/news-events/press-releases/detail/164/the-lovesac-company-reports-first-quarter-fiscal-2027 ; 10Q https://investor.lovesac.com/sec-filings/all-sec-filings/content/0001628280-26-061220/love-20260802.htm .

Premises1 Aug20 fullH1report p26, note4.4p33 https://telixpharma.com/wp-content/uploads/2026/08/H1-2026-Interim-Report.pdf directlyrecords OCF23.036m including40m collaborationreceipt.2 Python OCF lessPPE14.456/intangibles.332=8.248m; subtractleaseprincipal3.939 andothernoncurrent4.509=-.200m. Removing40m initialpayment givesOCF-16.964m/corecapexFCF-31.752m; analyticalsensitivity, notcounterfactualcompanyguidance.3 Customerreceipts+19.0532%vsOCF+29.7876%; cash251.910m supported bynetborrowingcash121m. RegeneroninitialIPcontribution recognizedotherincome, futurecost/profitsharing50/50.4 https://telixpharma.com/news-views/telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline/ retainsSep11Pixclara andunresolvedZircaixCRLresubmission; ATMdiscretionarynotprovenissuance. Conclusioncommercialgrowthisreal butheadlineOCFdoesnot establishrecurringcashorFDAstockedge. Counterexamplecollaboration economicallyvaluableandfuturecostsharing lowersburden; do notcallpaymentfakeorassumerunwayfromonehalfburn. Separatepipelineandmanufacturingcapitalmayabsorblaunchupside. SoundnesslimitedH1ratherthancurrentcash; currentdilutedvaluation/label/netlaunchmarginunverified. Noentry.

Premises1 June25issuerMay31FY2026source https://www.sec.gov/Archives/edgar/data/940944/000094094426000016/exhibit991-q4fy26.htm reports53weekFY;Q4salesgrowth13.7%includesextraweek7.6%;same-restaurant4.6%is13weekmetric.2 PythonQ4segmentprofit/salesOG24.25228%vs23.77987%,LongHorn21.17068%vs20.12473%;segmentprofitexcludescorporate/noncashitems,notnetmargin.3 OCF1853.1m-property734m-software22.9m=1096.2m;dividends693m+repurchases671.7m=1364.7m exceedsby268.5m,notproofofdistress.4 AtSep9close209.42 https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=DRI&timeframe=1Day&feed=sip&adjustment=all ,unchangedJuneFY27EPSguide11.10–11.35implies18.45–18.87x;quarterly1.62annualized6.48/3.0943%yieldisrunrate,notfourguaranteedpayments. Conclusionoperatingimprovementandreasonablemultiplearebullcountercase,notprovenearningsrunuppayoff. Validityvaluecontextcannotcalibratefive-sessionreturns. Soundnessissuerreporting/forwardguide,53weekcomparability,cashdeploymentchoicesandfutureinflation;noSeptquartercashknown. Start49.14cash;bindingconstraintvalidatedfeasiblenetedge. Noorder.

Premises1 Sep10Innate original notice confirmsSep17conference08EDT/14CEST, replacingearlieruncertain09ETreference: https://www.innate-pharma.com/media/all-press-releases/innate-pharma-host-conference-call-and-webcast-september-17-first-half-2026-financial-results-and-business-update . Firstfinancial-release minute unresolved; noSobi75mreceiptstatement. Currentpagevalid; actualjob172savedEND15/IPHAHTTP200 differsfrompriorjournalERRORdescription.2 FDX fiscalrecast https://www.sec.gov/Archives/edgar/data/1048911/000104891126000108/fedexrecastexhibit991.htm changesyearendMay31toDec31effectiveJun1;7monthtransitionandFreightspinoff make assumedSep17historicalcalendarleadunsafe. No verifiedreplacementearningsdate obtained. Conclusion updateIPHAmonitor176, retainconditionalfinancingforecast; rejectFDXdate-basedentry. Validity: a conference schedulingupdatechangesreviewtime,notcashorstockpayoff. Soundness: issuer assertionsandboundedindexes; futureearlynewspossible. Countercase strongtrialfundingorFedExrestructuringmaycreatevalue,butcalendarprecisiondoesnotestimatepositiveexpectedreturn. Researchonly,zeroallocation.

Premises:1 Aug14 offering exhibit projects runway throughQ1 2028 using equity PLUSUSD75mSobi closing payment; this supersedesAug10Q3 2027 for thecombinedcase. Source https://www.sec.gov/Archives/edgar/data/1598599/000162828026057935/exhibit993.htm . 2 Aug19filing confirms equitycompletedAug18,EUR27.6mexpectednet; priorityADC development, notexclusivelylacutamab. Source https://www.sec.gov/Archives/edgar/data/1598599/000162828026057935/a260819_6k1.htm .3 Sobi/InnatejointAug10agreement givescommercialrights onpotentialacceleratedapproval andoptiontoassumefulldevelopmentafterpositivePhase3; InnateconductsTELLOMAK3. Source https://www.sobi.com/en/press-releases/sobi-enters-strategic-partnership-innate-pharma-license-lacutamab-t-cell-lymphoma-2472935 .4 LatestMar31financialassets25.4mEURinclude4.9mshortterm+10.4mnoncurrent; Pythoncashresidual10.1m, notcurrentcash. Source https://www.innate-pharma.com/media/all-press-releases/innate-pharma-reports-first-quarter-2026-business-update-and-financial-results . Conclusion replace an imminent-unfunded-company baseline with materiallyimprovedconditionalrunway; doNOTassertcompletionfunding oractual75mreceipt. Soundness: officialissuersclosesttocontractbutincentivized; jointcopiesnotindependent; fullcostschedule/currentbalance/closingdocumentmissing. Validity: runwayforecastcannotlogicallyimplyfullyfundedrandomizedcompletion. Counterargument futuremilestones/royaltiescouldfinancecompletion; correct, sofuturefundinggap isunknown ratherthancertain. NextSep17reportmustreconcileclosing,subsequentevents,cashdefinition,burnandtrialcommitments. Noapprovalprobability orstocktargetfromfundingheadline.

Supersedes Maynegotiations-only context in1891/19169. Premise1 Aug10jointprimarySobi/Innateagreement promisesUSD75m ONCLOSING,upto40mnear-term and465mfurthermilestones/option, tiereddouble-digitroyalties; closingconditionsinclantitrust remain. Premise2 InnateconductsTELLOMAK3,Sobigetsglobalcommercialrights uponpotentialacceleratedapproval/eligibleglobaldevelopmentrightsafterpositiveP3. Premise3 Aug18equityraise27.6mEURexpectednet distinctfromUSDconditionalpayment andMarch25.4mfinancialassets. Conclusion materiallybetterfundingframeworkthanMay; precise currentcash/receipt/burn/retainedvalue stillunknown, noforcedcashrunwaybearcase. Boundaries:580mheadline75+40+465 isNOTcash today; noUSD/EURsum orprobability invented. Strongcountercase signedpartnershipcouldsupportstockrunup; executablepriceedge andliquidity stillfail (Sep9USD46.9ktrading,20daymedian56.9k). Consequence1 Sobi absorbscommercialrole,2 Innatecangeartrialspendingtocommittedfundingifcloses,3 retainedroyaltyeconomicsdependonsuccess/termsratherthanfullproductrevenue. Source https://www.sobi.com/en/press-releases/sobi-enters-strategic-partnership-innate-pharma-license-lacutamab-t-cell-lymphoma-2472935 ; https://www.innate-pharma.com/media/all-press-releases/innate-pharma-enters-strategic-partnership-sobi-license-lacutamab-t-cell-lymphoma . Sep2conference source https://www.sec.gov/Archives/edgar/data/1598599/000162828026059963/exhibit991-260902.htm confirmsSep14 16:30EDT; clinicalnewdata notpromised. No proposal.